# Pediatric Autism Cannabis: Doctor Discussion Guide & Clinical Letter Framework (2026) | Cฤ’D Clinic > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/advisor/pediatric-adolescent/autism/doctor-discussion-guide/ > **Published:** 2026-09-28T17:40:29-04:00 | **Last Modified / Clinically Audited:** 2026-10-06T21:54:15-04:00 > **Clinical Summary:** Cฤ’D CLINIC Pediatric Autism ๐Ÿงญ Visual Navigator Symptom Hubs โšก Aggression & Meltdowns Acute autonomic de-escalation & safety ๐ŸŒ™ Sleep & Circadian Insomnia Sleep latency, night waking & melatonin ๐Ÿ’ฌ Non-Verbal & Frustration Alternative communication & pain proxies ๐ŸŽ Gut-Brain Axis & ARFID Motility, sensory aversions & visceral discomfort ๐ŸŒช๏ธ Sensory Overload & Stimming Regulating […] --- [Cฤ’D CLINIC Pediatric Autism](https://cedclinic.com/advisor/pediatric-adolescent/autism/) [๐Ÿงญ Visual Navigator](https://cedclinic.com/advisor/pediatric-adolescent/visual-navigator/) [โšก Aggression & Meltdowns Acute autonomic de-escalation & safety](https://cedclinic.com/advisor/pediatric-adolescent/autism/aggression-and-meltdowns/) [๐ŸŒ™ Sleep & Circadian Insomnia Sleep latency, night waking & melatonin](https://cedclinic.com/advisor/pediatric-adolescent/autism/sleep-and-insomnia/) [๐Ÿ’ฌ Non-Verbal & Frustration Alternative communication & pain proxies](https://cedclinic.com/advisor/pediatric-adolescent/autism/non-verbal-communication-and-frustration/) [๐ŸŽ Gut-Brain Axis & ARFID Motility, sensory aversions & visceral discomfort](https://cedclinic.com/advisor/pediatric-adolescent/autism/gut-brain-axis-and-feeding/) [๐ŸŒช๏ธ Sensory Overload & Stimming Regulating striatal hyper-reactivity](https://cedclinic.com/advisor/pediatric-adolescent/complex-behavior/) [๐Ÿงฌ Rare Neurogenetic Syndromes Fragile X, SYNGAP1, Rett & CDKL5](https://cedclinic.com/advisor/pediatric-adolescent/genetic-syndromes/) [๐ŸŒฟ Oncology & Palliative Care Pediatric complex care & symptom support](https://cedclinic.com/advisor/pediatric-adolescent/oncology-palliative/) [๐ŸŽ’ Puberty & School Transition Hormonal shifts, IEPs & adolescent care](https://cedclinic.com/advisor/pediatric-adolescent/autism/puberty-adolescence-and-crisis/) Triage & Symptom Screeners [โš–๏ธ Meltdown vs. Seizure Triage Differentiate behavioral storms from subclinical seizures](https://cedclinic.com/advisor/pediatric-adolescent/autism/meltdown-shutdown-seizure-triage/) [๐Ÿฉน Silent Pain Proxy Checklist Identify hidden physical pain in non-verbal children](https://cedclinic.com/advisor/pediatric-adolescent/autism/silent-pain-somatic-proxy-checklist/) [๐Ÿฆ  Gut vs. Behavior Screener Connect GI reflux/motility to sudden agitation](https://cedclinic.com/advisor/pediatric-adolescent/autism/gut-vs-behavior-screener/) [โš ๏ธ Illness vs. Behavior (PANS) Distinguish infectious flares from neurobehavior](https://cedclinic.com/advisor/pediatric-adolescent/autism/illness-vs-behavior-screener/) [๐Ÿง  PDA vs. ODD Screener Demand avoidance rooted in nervous system threat](https://cedclinic.com/advisor/pediatric-adolescent/autism/pda-autism-vs-odd-nervous-system-screener/) Protocols & Care Plans [๐Ÿ’Š Medication Interaction Screen CYP450 metabolism & cross-taper safety](https://cedclinic.com/advisor/pediatric-adolescent/autism/medication-interactions/) [๐ŸŽ’ IEP & 504 Accommodations Clinical letter templates for schools](https://cedclinic.com/advisor/pediatric-adolescent/autism/autism-school-iep-504-medical-accommodation-guide/) [๐Ÿšช Elopement & Safety Plan First-responder emergency profiles](https://cedclinic.com/advisor/pediatric-adolescent/autism/autism-elopement-wandering-first-responder-safety-plan/) [๐Ÿ•’ Decompression Builder Prevent the 4:00 PM post-school crash](https://cedclinic.com/advisor/pediatric-adolescent/autism/after-school-decompression-builder/) [๐Ÿ›‹๏ธ Caregiver Sanctuary Parent nervous system recovery & cortisol balance](https://cedclinic.com/advisor/pediatric-adolescent/autism/caregiver-sanctuary/) [โš–๏ธ Pediatrician & DCF Guide Navigating Mandated Reporting & State Agencies](https://cedclinic.com/advisor/pediatric-adolescent/autism/pediatrician-and-dcf-guide/) [๐Ÿ›๏ธ Massachusetts Legal Guide Two-physician certification & legal protections](https://cedclinic.com/advisor/pediatric-adolescent/autism/massachusetts-pediatric-medical-cannabis-guide/) [๐Ÿ“‹ Doctor Discussion Script How to speak with hesitant neurologists & pediatricians](https://cedclinic.com/advisor/pediatric-adolescent/autism/doctor-discussion-guide/) [๐Ÿ“ Clinical Appointment Passport Organized dossier for medical teams](https://cedclinic.com/advisor/pediatric-adolescent/autism/pediatric-autism-clinical-passport-appointment-binder/) [๐Ÿ”ฌ The Science of Anandamide Endocannabinoid deficiency research in autism](https://cedclinic.com/advisor/pediatric-adolescent/autism/anandamide-and-cannabinoids/) [๐Ÿ“… Book Consult](https://cedclinic.com/book/) [๐Ÿงญ Open Visual Symptom Navigator](https://cedclinic.com/advisor/pediatric-adolescent/visual-navigator/) Symptom Hubs [โšก Aggression & Meltdowns](https://cedclinic.com/advisor/pediatric-adolescent/autism/aggression-and-meltdowns/) [๐ŸŒ™ Sleep & Insomnia](https://cedclinic.com/advisor/pediatric-adolescent/autism/sleep-and-insomnia/) [๐Ÿ’ฌ Non-Verbal & Frustration](https://cedclinic.com/advisor/pediatric-adolescent/autism/non-verbal-communication-and-frustration/) [๐ŸŽ Gut-Brain & Feeding](https://cedclinic.com/advisor/pediatric-adolescent/autism/gut-brain-axis-and-feeding/) [๐ŸŒช๏ธ Sensory Overload & Stimming](https://cedclinic.com/advisor/pediatric-adolescent/complex-behavior/) [๐Ÿงฌ Rare Neurogenetic Syndromes](https://cedclinic.com/advisor/pediatric-adolescent/genetic-syndromes/) [๐ŸŒฟ Oncology & Palliative Care](https://cedclinic.com/advisor/pediatric-adolescent/oncology-palliative/) [๐ŸŽ’ Puberty & School Transition](https://cedclinic.com/advisor/pediatric-adolescent/autism/puberty-adolescence-and-crisis/) Clinical Screeners & Tools [โš–๏ธ Meltdown vs. Seizure Triage](https://cedclinic.com/advisor/pediatric-adolescent/autism/meltdown-shutdown-seizure-triage/) [๐Ÿฉน Silent Pain Proxy Checklist](https://cedclinic.com/advisor/pediatric-adolescent/autism/silent-pain-somatic-proxy-checklist/) [๐Ÿฆ  Gut vs. Behavior Screener](https://cedclinic.com/advisor/pediatric-adolescent/autism/gut-vs-behavior-screener/) [โš ๏ธ Illness vs. Behavior Screener](https://cedclinic.com/advisor/pediatric-adolescent/autism/illness-vs-behavior-screener/) [๐Ÿ’Š Medication Interactions](https://cedclinic.com/advisor/pediatric-adolescent/autism/medication-interactions/) [๐ŸŽ’ School IEP & 504 Accommodations](https://cedclinic.com/advisor/pediatric-adolescent/autism/autism-school-iep-504-medical-accommodation-guide/) [๐Ÿšช Elopement & Safety Plan](https://cedclinic.com/advisor/pediatric-adolescent/autism/autism-elopement-wandering-first-responder-safety-plan/) [๐Ÿ›‹๏ธ Caregiver Sanctuary](https://cedclinic.com/advisor/pediatric-adolescent/autism/caregiver-sanctuary/) Family & Legal Guides [โš–๏ธ Pediatrician & DCF Guide](https://cedclinic.com/advisor/pediatric-adolescent/autism/pediatrician-and-dcf-guide/) [๐Ÿ›๏ธ Massachusetts Legal Guide](https://cedclinic.com/advisor/pediatric-adolescent/autism/massachusetts-pediatric-medical-cannabis-guide/) [๐Ÿ“‹ Doctor Discussion Script](https://cedclinic.com/advisor/pediatric-adolescent/autism/doctor-discussion-guide/) [๐Ÿ“ Clinical Passport Binder](https://cedclinic.com/advisor/pediatric-adolescent/autism/pediatric-autism-clinical-passport-appointment-binder/) [๐Ÿ“… Book Consultation with Dr. Caplan](https://cedclinic.com/book/) [Home](https://cedclinic.com/) โ€บ [Pediatrics](https://cedclinic.com/pediatrics/) โ€บ [Autism Clinical Hub](https://cedclinic.com/advisor/pediatric-adolescent/autism/) โ€บ Doctor Discussion Guide Clinical Practice Brief โ€ข Updated 2026 Table of Contents - [Autism & Cannabinoid Therapy: Doctor Discussion Guide & Clinical Letter Framework](#Autism_Cannabinoid_Therapy_Doctor_Discussion_Guide_Clinical_Letter_Framework)[1. The Collaborative Framework: Moving Beyond Hesitation](#1_The_Collaborative_Framework_Moving_Beyond_Hesitation) - [2. Physician-Specific Conversation Scripts](#2_Physician-Specific_Conversation_Scripts) - [3. The Physician's Clinical Corner: Pharmacokinetics & Safety](#3_The_Physicians_Clinical_Corner_Pharmacokinetics_Safety)[A. Cytochrome P450 (CYP450) Isoenzyme Interactions](#A_Cytochrome_P450_CYP450_Isoenzyme_Interactions) - [B. Laboratory Monitoring Recommendations](#B_Laboratory_Monitoring_Recommendations) - [4. Formal Clinical Notification Letter Template](#4_Formal_Clinical_Notification_Letter_Template)[Schedule a Clinical Consultation with Dr. Benjamin Caplan](#Schedule_a_Clinical_Consultation_with_Dr_Benjamin_Caplan) - [The Complete Cฤ’D Clinic Pediatric Autism Clinical Suite](#The_Complete_CED_Clinic_Pediatric_Autism_Clinical_Suite) - [Scientific Citations & Peer-Reviewed References](#Scientific_Citations_Peer-Reviewed_References) # Autism & Cannabinoid Therapy: Doctor Discussion Guide & Clinical Letter Framework A structured, physician-to-physician communication brief designed for parents and healthcare providers. Grounded in pharmacokinetic realities, peer-reviewed clinical trials, and collaborative multidisciplinary care. **Author:** Dr. Benjamin Caplan, MD (Chief Medical Officer, Cฤ’D Clinic) โ€ข **Target Audience:** Pediatricians, Neurologists, Child Psychiatrists & Caregivers ๐Ÿ“„ **Take this to your appointment:** Print this 2-page clinical brief or save it as a clean PDF for your child's medical team. ## 1. The Collaborative Framework: Moving Beyond Hesitation For most families navigating [Autism Spectrum Disorder](https://cedclinic.com/cbd-gummies-autism-symptoms-clinical/) (ASD), bringing up [medical cannabis](https://cedclinic.com/cbd-gummies-for-sexual-enhancement-evidence/) in a conventional pediatric exam room evokes intense vulnerability. Parents fear dismissive skepticism, moral judgment, or worst of all, triggering unnecessary child welfare reports. Conversely, primary care pediatricians and subspecialists frequently express anxiety because cannabinoid medicine was omitted from their medical school curricula and residency training [1]. **The Goal of this Document:** To establish immediate alignment. At Cฤ’D Clinic, we view medical cannabis not as an alternative to conventional medicine, but as an evidence-grounded, precision neuro-adjunct. When parents approach physicians with structured clinical terminology, explicit pharmacokinetic awareness, and transparent laboratory monitoring plans, defensive walls dissolve into genuine multidisciplinary collaboration. **The Golden Clinical Rule for Families:** Never present cannabis as a miracle cure or an ideological rejection of conventional pharmaceuticals. Present it as a targeted, physician-supervised trial aimed at mitigating debilitating autonomic agitation, refractory sleep architecture breakdown, or sensory overload [2]. ## 2. Physician-Specific Conversation Scripts Different medical specialists evaluate clinical interventions through distinct professional lenses. Use the following scripts tailored specifically to the doctor sitting across from you. ๐Ÿฉบ Script A: For the General Pediatrician "Dr. [Physician Last Name], we value your primary guidance in [Child's Name]'s health above all. As you know, we have reached a plateau with our current behavioral strategies, and [he/she] is suffering from severe circadian disruptions and sensory distress that impair daily functioning. We are not considering recreational products or internet hearsay. We are consulting with a licensed physician who specializes in pediatric cannabinoid medicine (Dr. Benjamin Caplan at Cฤ’D Clinic). Our plan is to explore a low-dose, laboratory-verified, full-spectrum cannabinoid regimen (CBD/CBG with micro-THC ratios) under strict medical supervision. We want you fully integrated into this process. We will ensure every formulation's third-party Certificate of Analysis (COA) is documented, we will provide you with full titration logs, and we want to coordinate any recommended routine lab monitoring (such as hepatic panels) with your office." **Why this works:** It respects their authority as primary medical gatekeeper, establishes that you have retained qualified physician oversight, and disarms fears of secretive or unregulated self-medication. ๐Ÿง  Script B: For the Pediatric Neurologist "Dr. [Neurologist Last Name], we know that excitation/inhibition (E/I) imbalance and endocannabinoid tone deficiencies are heavily documented in autism pathophysiology [3, 4]. Because [Child's Name] exhibits persistent motor agitation, central sensory flooding, and intermittent subclinical spike-wave activity, we want to evaluate an adjunctive phytocannabinoid regimen. Before introducing any formulation, we want to cross-reference our protocol against [Child's Name]'s current medicationsโ€”specifically looking at CYP450 enzyme competitive pathways (CYP3A4 and CYP2C19) to ensure we do not artificially shift serum concentrations of [Current Anticonvulsant / Mood Stabilizer] [5]. We would appreciate your guidance on baseline EEG or metabolic parameters so we can monitor neurological stability objectively." **Why this works:** Neurologists respond to neurobiological mechanisms: GABA/Glutamate ratio, endocannabinoid tone (anandamide levels), and hepatic cytochrome P450 isoenzyme kinetics. ๐Ÿ’Š Script C: For the Child Psychiatrist "Dr. [Psychiatrist Last Name], we understand the rationale behind prescribing [Risperidone / Aripiprazole / Guanfacine], but we are very concerned about the long-term metabolic, endocrine, and extrapyramidal burdens on [Child's Name]'s body. We would like to introduce a medically supervised cannabinoid trial as a co-therapy, with the explicit long-term clinical goal of establishing neuro-calm and, if clinically indicated, exploring a slow, micro-taper of [Medication Name] [6]. We will not adjust any psychotropic medications independently. We want to work directly with you to establish a shared clinical rating scale for aggression and meltdown frequency so we can assess whether cannabinoid co-therapy allows for a lower pharmaceutical burden." **Why this works:** Psychiatrists frequently feel trapped between the black-box side effects of atypical antipsychotics and violent dysregulation. Framing cannabinoids as a gentle off-ramp or dose-sparing adjunct invites them to participate in safe deprescribing. ## 3. The Physician's Clinical Corner: Pharmacokinetics & Safety The following technical summary is designed for your child's medical providers. You may invite them to review this section directly during your clinical consultation. ### A. Cytochrome P450 (CYP450) Isoenzyme Interactions Phytocannabinoids, particularly Cannabidiol (CBD), are metabolized extensively by the hepatic cytochrome P450 system and act as competitive inhibitors of specific isoenzymes [5, 7]: Enzyme Cannabinoid Kinetic Effect Co-Administered Autism Medications Clinical Monitoring Rule **CYP2C19** Potent CBD competitive inhibition Clobazam (Onfi), Diazepam, Sertraline Inhibition blocks conversion of active metabolite *N-desmethylclobazam*, potentially increasing sedation 3-fold. Titrate clobazam downward if lethargy occurs [5]. **CYP3A4** Moderate CBD & THC competitive inhibition Aripiprazole (Abilify), Clonidine, Guanfacine, Quetiapine May elevate serum concentrations of antipsychotics. Monitor for excessive drowsiness, orthostasis, or bradycardia. **CYP2D6** Mild-to-moderate inhibition Risperidone, Fluoxetine, Atomoxetine Risperidone is converted to 9-hydroxyrisperidone via CYP2D6. Monitor prolactin levels and extrapyramidal symptoms. **Hepatic Transaminases** Additive hepatocellular burden Valproic Acid / Divalproex (Depakote) Co-administration of high-dose CBD with valproate poses an increased risk of ALT/AST elevation. Mandatory baseline and 60-day LFT monitoring required [9]. **Mandatory Safety Boundary:** At Cฤ’D Clinic, all cannabinoid administrations must be separated from oral psychiatric pharmaceuticals by a minimum 2-hour metabolic buffer window to minimize peak competitive gut and hepatic first-pass enzymatic overlap. ### B. Laboratory Monitoring Recommendations To ensure unimpeachable safety, pediatric cannabinoid regimens should be accompanied by standard objective laboratory markers: - **Baseline:** Comprehensive Metabolic Panel (CMP including ALT, AST, total bilirubin, BUN, creatinine) and Complete Blood Count (CBC). - **60 to 90 Days Post-Titration:** Repeat CMP if co-administered with anticonvulsants (valproate, clobazam) or high-dose broad-spectrum CBD (>5 mg/kg/day). - **Prolactin & Fasting Lipids:** If tapering off atypical antipsychotics (Risperidone / Aripiprazole), track serum prolactin, fasting blood glucose, and lipid panels every 6 months until stabilization. ## 4. Formal Clinical Notification Letter Template Parents may download, customize, and deliver this formal letter to their child's medical record or patient portal prior to their annual or specialty visit. Date: [Date] To: Dr. [Doctor's Full Name], [Pediatric Specialty / Clinic Name] Re: Collaborative Medical Notification: Adjunctive [Cannabinoid Therapy](https://cedclinic.com/cbd-gummies-libido-enhancement/) Patient Name: [Child's Full Name] | DOB: [Child's Date of Birth] | MRN: [Medical Record #] Dear Dr. [Doctor's Last Name], We are writing to provide formal, transparent documentation that [Child's Name] is initiating an adjunctive, physician-supervised trial of medical cannabinoid therapy under the clinical direction of Dr. Benjamin Caplan, MD (Cฤ’D Clinic, Needham, MA). The clinical indications for this trial include refractory neuro-behavioral dysregulation, severe sleep latency/wake fragmentation, and sensory-induced autonomic hyper-arousal associated with [his/her] Autism Spectrum Disorder. Please note the following safety and clinical governance protocols established for [Child's Name]: 1. FORMULATION INTEGRITY: All products utilized are non-combustible, pharmaceutical-grade oral tinctures accompanied by verified, third-party batch Certificates of Analysis (COAs) confirming exact cannabinoid ratios and absence of heavy metals, pesticides, mycotoxins, and residual solvents. 2. PHARMACOKINETIC BUFFER: Dosing is timed with a minimum 2-hour separation from any concurrent pharmaceutical medications to minimize hepatic Cytochrome P450 (CYP3A4/CYP2C19) competition. 3. ADJUNCTIVE OBJECTIVE: We are not discontinuing or altering any prescribed medications independently. Any future adjustments or slow weaning of conventional psychotropics will be executed strictly in direct consultation with your office. 4. LAB MONITORING: We welcome your order for routine baseline or surveillance hepatic transaminase (LFT) panels as deemed appropriate. We deeply value your ongoing care and partnership. Should your office require clinical records, titration notes, or direct peer-to-peer discussion, Dr. Caplan's clinical team can be reached directly at (617) 500-2808 or via secure medical correspondence at info@cedclinic.com. Sincerely, _________________________________________ _________________________________________ [Parent/Guardian Signature] [Parent/Guardian Printed Name] Contact Phone: [Parent Phone Number] Email: [Parent Email Address] Physician Consultation ### Schedule a Clinical Consultation with Dr. Benjamin Caplan Every child's neurobiology is unique. At Cฤ’D Clinic, we provide comprehensive pediatric and adolescent clinical evaluations, review medication regimens, and design safe, physician-supervised cannabinoid protocols. [Book an Appointment โ†’](https://cedclinic.com/book/) ### The Complete Cฤ’D Clinic Pediatric Autism Clinical Suite This Doctor Discussion Guide is part of our integrated 2026 clinical suite. Explore our evidence guides, interactive triage tools, and foundational series: [๐Ÿ›๏ธ Autism Clinical Hub The master pillar exploring the 4 developmental stages, receptor mechanics, and evidence compendium.](https://cedclinic.com/advisor/pediatric-adolescent/autism/) [๐Ÿ“Š What We're Learning Gallery Master developmental infographic and clinical lessons distilled from hundreds of patient families.](https://cedclinic.com/advisor/pediatric-adolescent/autism/what-were-learning/) [๐Ÿ’Š Medication Deprescribing Part 6 of our blog series: Safe tapering strategies, rebound rage buffers, and clinical coordination.](https://cedclinic.com/autism-medication-weaning-deprescribing-roadmap/) [๐Ÿ‘ถ Main Pediatric Practice Comprehensive pediatric cannabis medicine, scheduling consultations, and state registry support.](https://cedclinic.com/pediatrics/) ### Scientific Citations & Peer-Reviewed References - Aran A, Cassuto H, Lubotzky A, Hevroni N, Greenfield M. *Brief Report: Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problemsโ€”A Retrospective Feasibility Study.* **Journal of Autism and Developmental Disorders**. 2019;49(3):1284-1288. [PubMed PMID: 30382443](https://pubmed.ncbi.nlm.nih.gov/30382443/). - Bar-Lev Schleider L, Mechoulam R, Saban N, Meiri G, Novack V. *Real life Experience of Medical Cannabis Treatment in Autism: Analysis of Safety and Efficacy.* **Scientific Reports (Nature)**. 2019;9(1):200. [PubMed PMID: 30655581](https://pubmed.ncbi.nlm.nih.gov/30655581/). - Karhson DS, Krasinska KM, Dallaire JA, et al. *Plasma anandamide concentrations are lower in children with autism spectrum disorder.* **Molecular Autism**. 2018;9(1):18. [PubMed PMID: 29556353](https://pubmed.ncbi.nlm.nih.gov/29556353/). - Pretzsch CM, Freyberg J, Voinescu B, et al. *Call for clinical trials of cannabinoids in autism: A qualitative systemic review and neurobiological rationale.* **Neuropsychopharmacology**. 2019;44(8):1398โ€“1405. [PubMed PMID: 30755716](https://pubmed.ncbi.nlm.nih.gov/30755716/). - Gaston TE, Bebin EM, Cutter GR, Liu Y, Szaflarski JP. *Interactions between cannabidiol and commonly used antiepileptic drugs.* **Epilepsia**. 2017;58(9):1586-1592. [PubMed PMID: 28782097](https://pubmed.ncbi.nlm.nih.gov/28782097/). - Rong C, Carmona NE, Lee YL, et al. *Cannabinoids in the treatment of autism spectrum disorder: a systematic review.* **Neurotherapeutics**. 2021;18(4):1874-1888. [PubMed PMID: 34297380](https://pubmed.ncbi.nlm.nih.gov/34297380/). - Iffland K, Grotenhermen F. *An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies.* **Cannabis and Cannabinoid Research**. 2017;2(1):139โ€“154. [PubMed PMID: 28861514](https://pubmed.ncbi.nlm.nih.gov/28861514/). - Poleg S, Golubchik P, Offen D, Weizman A. *Cannabinoids in autism spectrum disorders: Clinical overview and neurobiological mechanisms.* **Progress in Neuro-Psychopharmacology and Biological Psychiatry**. 2021;111:110398. [PubMed PMID: 34090956](https://pubmed.ncbi.nlm.nih.gov/34090956/). - Devinsky O, Cross JH, Laux L, et al. *Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.* **New England Journal of Medicine**. 2017;376(21):2011-2020. [PubMed PMID: 28538134](https://pubmed.ncbi.nlm.nih.gov/28538134/). --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR ยง 164.514(b)) and criteria for secondary research exemption under 45 CFR ยง 46.104(d)(4).